Last reviewed · How we verify
Zmax
Zmax (azithromycin extended-release) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Zmax (azithromycin extended-release) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.
At a glance
| Generic name | Zmax |
|---|---|
| Sponsor | Pfizer |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin works by binding to bacterial ribosomes and blocking peptide translocation, thereby preventing protein synthesis and bacterial growth. The extended-release formulation allows for once-daily dosing with sustained drug levels. It has both bacteriostatic activity against susceptible organisms and some immunomodulatory properties.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute bacterial exacerbation of chronic bronchitis
- Otitis media
- Pharyngitis/tonsillitis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Headache
- QT prolongation
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study of Standard Drugs for Mycobacterium Avium Complex (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Antibiotic Treatment of Recurrent Episodes of Asthma in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zmax CI brief — competitive landscape report
- Zmax updates RSS · CI watch RSS
- Pfizer portfolio CI